Vipivotide Tetraxetan consists of a peptide vector linked to a tetraxetan chelator optimized for radiometal coordination in receptor-targeted research. The peptide motif directs binding, while the macrocyclic chelator ensures controlled metal complexation. Researchers assess stability, binding geometry, and solution behavior. Applications include radiometal-ligand modeling, receptor-mapping studies, and chelator-optimization projects.
CAT No: PI-026
CAS No:1702967-37-0
Synonyms/Alias:Vipivotide tetraxetan;PSMA-617;1702967-37-0;PSMA617 TFA;DKFZ-PSMA-617;PSMA617;4YM1W0EGQ5;Vipivotide tetraxetan [INN];Vipivotide tetraxetan [USAN];Vipivotide tetraxetan (PSMA-617);1702967-37-0 (free base);(((S)-1-Carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid;(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid;(((S)-1-carboxy-5-((S)-3-(naphthalen-2-yl)-2-((1r,4S)-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carboxamido)propanamido)pentyl)carbamoyl)-L-glutamic acid tetra(trifluoroacetic acid);L-Lysine, N2-((((1S)-1,3-dicarboxypropyl)amino)carbonyl)-N6-(3-(2-naphthalenyl)-N-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetyl)-L-alanyl-trans-4-(aminomethyl)cyclohexanecarbonyl)-;N-((N6-(3-(Naphthalen-2-yl)-N-(trans-4-((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)cyclohexane-1-carbonyl)-L-alanyl)-llysin-N2-yl)carbonyl)-L-glutamic acid;N2-((((1S)-1,3-Dicarboxypropyl)amino)carbonyl)-N6-(3-(2-naphthalenyl)-N-((trans-4-(((2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetyl)amino)methyl)cyclohexyl)carbonyl)-L-alanyl)-L-lysine;Vipivotida tetraxetan;UNII-4YM1W0EGQ5;CHEMBL4594280;SCHEMBL20180896;SCHEMBL21316439;SCHEMBL21501570;GTPL11982;PSMA-617?;Vipivotide tetraxetan (USAN/INN);Vipivotide tetraxetan [USAN:INN];CTC96737;EX-A5885;BDBM50544833;s8670;WHO 11010;AKOS040735693;DA-77204;MS-31892;HY-117410;CS-0065894;D11697;F82270;-LYSINE, N2-((((1S)-1,3-DICARBOXYPROPYL)AMINO)CARBONYL)-N6-(3-(2-NAPHTHALENYL)-N-((TRANS-4-(((2-(4,7,10-TRIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL)AMINO)METHYL)CYCLOHEXYL)CARBONYL)--ALANYL)-;PSMA-617; L-Lysine, N2-[[[(1S)-1,3-dicarboxypropyl]amino]carbonyl]-N6-[3-(2-naphthalenyl)-N-[[trans-4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]amino]methyl]cyclohexyl]carbonyl]-L-alanyl]-; N2-[[[(1S)-1,3-Dicarboxypropyl]amino]carbony;
Vipivotide tetraxetan, also known as PSMA-617, is a synthetic small molecule designed to target the prostate-specific membrane antigen (PSMA), which is highly expressed on the surface of certain cancer cells, most notably prostate cancer. As a low molecular weight peptidomimetic, Vipivotide tetraxetan demonstrates strong affinity and specificity for PSMA, allowing for precise targeting in a variety of scientific and research contexts. Its robust structure enables conjugation with a range of radiometals or imaging agents, making it a versatile tool in molecular biology, radiochemistry, and pharmacological studies. The molecule's unique chelator backbone allows for stable complexation with radionuclides, supporting its use in innovative research focused on targeted delivery and molecular imaging. Vipivotide tetraxetan has gained significant attention in the scientific community due to its modular design, which facilitates the development of advanced diagnostic and investigative strategies in both in vitro and in vivo settings.
Radiolabeling and Molecular Imaging: Vipivotide tetraxetan is widely utilized in radiolabeling applications, where it serves as a chelator for various radiometals, such as lutetium-177 or gallium-68, enabling the creation of radiopharmaceuticals for preclinical imaging studies. By attaching a radionuclide to the PSMA-targeting molecule, researchers can visualize and track the biodistribution and tumor-targeting efficacy of the compound in animal models. This approach supports the evaluation of new imaging agents and provides valuable insights into the pharmacokinetics and targeting capabilities of PSMA-directed molecules, advancing the field of molecular imaging.
Targeted Drug Delivery Research: In the realm of targeted drug delivery, PSMA-617 is employed as a targeting moiety for the selective delivery of therapeutic payloads to PSMA-expressing cells. Scientists can conjugate cytotoxic agents, nanoparticles, or other bioactive compounds to the ligand, exploiting its high binding affinity for PSMA to achieve enhanced accumulation in the desired tissues. This strategy is instrumental in the development of new targeted delivery systems, allowing for the assessment of drug distribution, cellular uptake, and therapeutic efficacy in preclinical models, while minimizing off-target effects and improving the selectivity of experimental therapeutics.
Biodistribution and Pharmacokinetic Studies: Researchers leverage Vipivotide tetraxetan in studies designed to elucidate the biodistribution and pharmacokinetic profiles of PSMA-targeted compounds. By radiolabeling or fluorescently tagging the molecule, it becomes possible to track its movement throughout biological systems and quantify its accumulation in specific tissues. These investigations provide critical data on tissue specificity, retention times, and clearance mechanisms, informing the design and optimization of next-generation targeting agents and supporting translational research efforts in molecular pharmacology.
Receptor Binding and Mechanistic Investigations: The high specificity of PSMA-617 for its target makes it a valuable tool in receptor binding assays and mechanistic studies. Scientists can use the compound to probe PSMA expression levels, binding kinetics, and receptor-mediated internalization in cellular models. These studies contribute to a deeper understanding of PSMA biology, receptor-ligand interactions, and the mechanisms underlying selective targeting. Such insights are essential for the rational design of new ligands, the validation of PSMA as a research target, and the exploration of resistance mechanisms in experimental systems.
Theranostic Platform Development: Vipivotide tetraxetan plays a pivotal role in the development of theranostic platforms, which integrate diagnostic and therapeutic functionalities within a single molecular construct. By leveraging its chelator moiety, researchers can create dual-purpose agents that enable both imaging and therapeutic interventions in preclinical research. This approach facilitates real-time monitoring of compound distribution and therapeutic response, supporting the refinement of personalized treatment strategies and the advancement of precision medicine research in laboratory settings.
In summary, Vipivotide tetraxetan's unique chemical properties and high target specificity underpin its broad utility in radiolabeling and molecular imaging, targeted drug delivery research, biodistribution and pharmacokinetic studies, receptor binding and mechanistic investigations, as well as theranostic platform development. Its modularity and versatility continue to drive innovation across multiple scientific disciplines, providing researchers with a powerful tool for the advancement of molecular targeting technologies and the exploration of new frontiers in biomedical research.
1. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
2. The spatiotemporal control of signalling and trafficking of the GLP-1R
4. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More